198 related articles for article (PubMed ID: 19835057)
21. T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity.
Schmid DA; Depta JP; Pichler WJ
Clin Exp Allergy; 2006 Jan; 36(1):59-69. PubMed ID: 16393267
[TBL] [Abstract][Full Text] [Related]
22. Antigen receptors on Thy-1+ CD3- CS-initiating cell. In vitro desensitization with hapten-amino acid or hapten-Ficoll conjugates, versus hapten-protein conjugates, suggests different antigen receptors on the immune cells that mediate the early and late components of murine contact sensitivity.
Garssen J; Van Loveren H; Kato K; Askenase PW
J Immunol; 1994 Jul; 153(1):32-44. PubMed ID: 7911496
[TBL] [Abstract][Full Text] [Related]
23. Role of dendritic cells in drug allergy.
Blázquez AB; Cuesta J; Mayorga C
Curr Opin Allergy Clin Immunol; 2011 Aug; 11(4):279-84. PubMed ID: 21659861
[TBL] [Abstract][Full Text] [Related]
24. Interaction of sulfonamide derivatives with the TCR of sulfamethoxazole-specific human alpha beta+ T cell clones.
von Greyerz S; Zanni MP; Frutig K; Schnyder B; Burkhart C; Pichler WJ
J Immunol; 1999 Jan; 162(1):595-602. PubMed ID: 9886437
[TBL] [Abstract][Full Text] [Related]
25. Modes of presentation of chemical neoantigens to the immune system.
Pichler WJ
Toxicology; 2002 Dec; 181-182():49-54. PubMed ID: 12505284
[TBL] [Abstract][Full Text] [Related]
26. Metabolic and chemical origins of cross-reactive immunological reactions to arylamine benzenesulfonamides: T-cell responses to hydroxylamine and nitroso derivatives.
Castrejon JL; Lavergne SN; El-Sheikh A; Farrell J; Maggs JL; Sabbani S; O'Neill PM; Park BK; Naisbitt DJ
Chem Res Toxicol; 2010 Jan; 23(1):184-92. PubMed ID: 19954178
[TBL] [Abstract][Full Text] [Related]
27. T-cell response in penicillin allergy.
Padovan E
Clin Exp Allergy; 1998 Sep; 28 Suppl 4():33-6. PubMed ID: 9761028
[TBL] [Abstract][Full Text] [Related]
28. Carrier and hapten functions in immune deviation. I. Contrary effects of hapten and carrier on cellular and helper functions of T cells.
Neveu PJ; Borduas AG
Immunology; 1975 Feb; 28(2):315-22. PubMed ID: 47307
[TBL] [Abstract][Full Text] [Related]
29. Presentation of non-peptide antigens, in particular drugs, to specific T cells.
von Greyerz S; Zanni M; Schnyder B; Pichler WJ
Clin Exp Allergy; 1998 Sep; 28 Suppl 4():7-11. PubMed ID: 9761023
[TBL] [Abstract][Full Text] [Related]
30. In vitro primary sensitization of hapten-specific T cells by cultured human epidermal Langerhans cells--a screening predictive assay for contact sensitizers.
Krasteva M; Peguet-Navarro J; Moulon C; Courtellemont P; Redziniak G; Schmitt D
Clin Exp Allergy; 1996 May; 26(5):563-70. PubMed ID: 8735869
[TBL] [Abstract][Full Text] [Related]
31. Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity.
Depta JP; Altznauer F; Gamerdinger K; Burkhart C; Weltzien HU; Pichler WJ
J Allergy Clin Immunol; 2004 Mar; 113(3):519-27. PubMed ID: 15007356
[TBL] [Abstract][Full Text] [Related]
32. Drug hypersensitivity: flare-up reactions, cross-reactivity and multiple drug hypersensitivity.
Pichler WJ; Daubner B; Kawabata T
J Dermatol; 2011 Mar; 38(3):216-21. PubMed ID: 21342222
[TBL] [Abstract][Full Text] [Related]
33. Predictive drug allergy testing: an alternative viewpoint.
Pichler WJ
Toxicology; 2001 Feb; 158(1-2):31-41. PubMed ID: 11164990
[TBL] [Abstract][Full Text] [Related]
34. Determinant specific suppression of antigen-induced T cell proliferation in the guinea pig. II. Determinant specific suppression of in vitro T cell responsiveness parallels a selective suppression of anti-hapten but not anti-carrier antibody responses.
Baskin BL; Blake JT; Rosenthal AS
J Immunol; 1980 Jan; 124(1):189-93. PubMed ID: 6153095
[TBL] [Abstract][Full Text] [Related]
35. Drug hypersensitivity.
Yawalkar N
Acta Clin Belg; 2009; 64(6):529-33. PubMed ID: 20101877
[TBL] [Abstract][Full Text] [Related]
36. In vitro primary sensitization and restimulation of hapten-specific T cells by fresh and cultured human epidermal Langerhans' cells.
Moulon C; Péguet-Navarro J; Courtellemont P; Redziniak G; Schmitt D
Immunology; 1993 Nov; 80(3):373-9. PubMed ID: 7507088
[TBL] [Abstract][Full Text] [Related]
37. Recognition of hapten-modified cells in vitro by human T-lymphocytes.
Seldin MF; Rich RR; Abramson SL
J Clin Invest; 1979 Oct; 64(4):967-76. PubMed ID: 314454
[TBL] [Abstract][Full Text] [Related]
38. Delayed drug hypersensitivity: models of T-cell stimulation.
Adam J; Pichler WJ; Yerly D
Br J Clin Pharmacol; 2011 May; 71(5):701-7. PubMed ID: 21480949
[TBL] [Abstract][Full Text] [Related]
39. Carrier and hapten functions in immune deviation. II. Role of hapten and carrier on the helper functions of the T cells.
Neveu PJ; Borduas AG
Immunology; 1975 Mar; 28(3):553-9. PubMed ID: 47838
[TBL] [Abstract][Full Text] [Related]
40. Molecular aspects of drug recognition by specific T cells.
Britschgi M; von Greyerz S; Burkhart C; Pichler WJ
Curr Drug Targets; 2003 Jan; 4(1):1-11. PubMed ID: 12528985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
